Biological Evaluation of 3-Benzylidenechromanones and Their Spiropyrazolines-Based Analogues. 2020

Angelika A Adamus-Grabicka, and Magdalena Markowicz-Piasecka, and Marcin Cieślak, and Karolina Królewska-Golińska, and Paweł Hikisz, and Joachim Kusz, and Magdalena Małecka, and Elzbieta Budzisz
Department of Cosmetic Raw Materials Chemistry, Faculty of Pharmacy, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.

A series of 3-benzylidenechrmanones 1, 3, 5, 7, 9 and their spiropyrazoline analogues 2, 4, 6, 8, 10 were synthesized. X-ray analysis confirms that compounds 2 and 8 crystallize in a monoclinic system in P21/n space groups with one and three molecules in each asymmetric unit. The crystal lattice of the analyzed compounds is enhanced by hydrogen bonds. The primary aim of the study was to evaluate the anti-proliferative potential of 3-benzylidenechromanones and their spiropyrazoline analogues towards four cancer cell lines. Our results indicate that parent compounds 1 and 9 with a phenyl ring at C2 have lower cytotoxic activity against cancer cell lines than their spiropyrazolines analogues. Analysis of IC50 values showed that the compounds 3 and 7 exhibited higher cytotoxic activity against cancer cells, being more active than the reference compound (4-chromanone or quercetin). The results of this study indicate that the incorporation of a pyrazoline ring into the 3-arylideneflavanone results in an improvement of the compounds' activity and therefore it may be of use in the search of new anticancer agents. Further analysis allowed us to demonstrate the compounds to have a strong inhibitory effect on the cell cycle. For instance, compounds 2, 10 induced 60% of HL-60 cells to be arrested in G2/M phase. Using a DNA-cleavage protection assay we also demonstrated that tested compounds interact with DNA. All compounds at the concentrations corresponding to cytotoxic properties are not toxic towards red blood cells, and do not contribute to hemolysis of RBCs.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002867 Chromones 1,4-Benzopyrones,Chromone,1,4 Benzopyrones
D006461 Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity. Haemolysis,Extravascular Hemolysis,Intravascular Hemolysis,Extravascular Hemolyses,Haemolyses,Hemolyses, Extravascular,Hemolyses, Intravascular,Hemolysis, Extravascular,Hemolysis, Intravascular,Intravascular Hemolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006860 Hydrogen Bonding A low-energy attractive force between hydrogen and another element. It plays a major role in determining the properties of water, proteins, and other compounds. Hydrogen Bonds,Bond, Hydrogen,Hydrogen Bond
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Angelika A Adamus-Grabicka, and Magdalena Markowicz-Piasecka, and Marcin Cieślak, and Karolina Królewska-Golińska, and Paweł Hikisz, and Joachim Kusz, and Magdalena Małecka, and Elzbieta Budzisz
November 2016, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society,
Angelika A Adamus-Grabicka, and Magdalena Markowicz-Piasecka, and Marcin Cieślak, and Karolina Królewska-Golińska, and Paweł Hikisz, and Joachim Kusz, and Magdalena Małecka, and Elzbieta Budzisz
July 2022, ACS omega,
Angelika A Adamus-Grabicka, and Magdalena Markowicz-Piasecka, and Marcin Cieślak, and Karolina Królewska-Golińska, and Paweł Hikisz, and Joachim Kusz, and Magdalena Małecka, and Elzbieta Budzisz
August 2002, Bioorganic & medicinal chemistry letters,
Angelika A Adamus-Grabicka, and Magdalena Markowicz-Piasecka, and Marcin Cieślak, and Karolina Królewska-Golińska, and Paweł Hikisz, and Joachim Kusz, and Magdalena Małecka, and Elzbieta Budzisz
February 2016, European journal of medicinal chemistry,
Angelika A Adamus-Grabicka, and Magdalena Markowicz-Piasecka, and Marcin Cieślak, and Karolina Królewska-Golińska, and Paweł Hikisz, and Joachim Kusz, and Magdalena Małecka, and Elzbieta Budzisz
December 2017, Bioorganic & medicinal chemistry,
Angelika A Adamus-Grabicka, and Magdalena Markowicz-Piasecka, and Marcin Cieślak, and Karolina Królewska-Golińska, and Paweł Hikisz, and Joachim Kusz, and Magdalena Małecka, and Elzbieta Budzisz
December 1990, Archiv der Pharmazie,
Angelika A Adamus-Grabicka, and Magdalena Markowicz-Piasecka, and Marcin Cieślak, and Karolina Królewska-Golińska, and Paweł Hikisz, and Joachim Kusz, and Magdalena Małecka, and Elzbieta Budzisz
September 2015, Journal of medicinal chemistry,
Angelika A Adamus-Grabicka, and Magdalena Markowicz-Piasecka, and Marcin Cieślak, and Karolina Królewska-Golińska, and Paweł Hikisz, and Joachim Kusz, and Magdalena Małecka, and Elzbieta Budzisz
February 2018, Journal of medicinal chemistry,
Angelika A Adamus-Grabicka, and Magdalena Markowicz-Piasecka, and Marcin Cieślak, and Karolina Królewska-Golińska, and Paweł Hikisz, and Joachim Kusz, and Magdalena Małecka, and Elzbieta Budzisz
January 1982, Journal of medicinal chemistry,
Angelika A Adamus-Grabicka, and Magdalena Markowicz-Piasecka, and Marcin Cieślak, and Karolina Królewska-Golińska, and Paweł Hikisz, and Joachim Kusz, and Magdalena Małecka, and Elzbieta Budzisz
April 2021, Chemistry (Weinheim an der Bergstrasse, Germany),
Copied contents to your clipboard!